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vidence is provided that proteolytic cleavage of col-
lagen type IV results in the exposure of a functionally
important cryptic site hidden within its triple helical
structure. Exposure of this cryptic site was associated with
angiogenic, but not quiescent, blood vessels and was re-
quired for angiogenesis in vivo. Exposure of the HUIV26
 
epitope was associated with a loss of 
 
 
 
1
 
 
 
1 integrin bind-
E
 
ing and the gain of 
 
 
 
v
 
 
 
3 binding. A monoclonal antibody
(HUIV26) directed to this site disrupts integrin-dependent
endothelial cell interactions and potently inhibits angio-
genesis and tumor growth. Together, these studies suggest a
novel mechanism by which proteolysis contributes to an-
giogenesis by exposing hidden regulatory elements within
matrix-immobilized collagen type IV.
 
Introduction
 
The extracellular matrix (ECM)* is an interconnected molec-
ular network that not only provides mechanical support for
cells and tissues, but also regulates biochemical and cellu-
lar processes such as adhesion, migration, gene expression,
and differentiation (Timpl and Brown, 1995; Timpl, 1996;
Herbst et al., 1998; Tsai, 1998; Dogic et al., 1999). A special-
ized form of the ECM that separates epithelia from its under-
lying mesenchyme and lines blood vessels is the basement
membrane (Timpl and Brown, 1995; Timpl, 1996). Al-
though considerable progress has been made in understanding
the roles of growth factors and integrin receptors in the pro-
cess of angiogenesis, little is known concerning the role that
basement membrane degradation plays in this process. Matrix
degradation may simply provide a mechanism to remove a re-
strictive physical barrier that limits endothelial motility. Alter-
natively, ECM remodeling may release matrix-sequestered
growth factors that promote endothelial cell proliferation and
migration. However, the possibility that matrix remodeling
does not simply destroy matrix barrier, but rather selectively
exposes cryptic protein sequences that play an functional role
in angiogenesis has not been explored in depth.
A major component of the vascular basement membrane
is collagen type IV (Hudson et al., 1993). The most widely
expressed form is composed of two 
 
 
 
1(IV) chains and one
 
 
 
2(IV) chain and is found in the basement membrane of
virtually all blood vessels. Interestingly, the triple helical na-
ture of collagen is thought to regulate integrin-mediated cel-
lular interactions (Messent et al., 1998; Emsley et al., 2000).
In fact, proteolytic cleavage and denaturation can convert
triple helical collagen type I from a 
 
 
 
1 integrin–directed
ECM ligand to an 
 
 
 
v
 
 
 
3-dependent ligand (Davis, 1992;
Montgomery et al., 1994). This shift in integrin-mediated
 
interactions may represent an important regulatory mech-
anism to activate distinct signal transduction pathways
necessary for invasive cellular behavior. However, no di-
rect evidence is available to indicate that interaction of
denatured collagen with endothelial cells is a functionally
important step in angiogenesis.
Here, we provide evidence that proteolytic cleavage of col-
lagen type IV can expose a cryptic site which is normally hid-
den within its triple helical structure. This cryptic site was
 
Address correspondence to Peter C. Brooks, Departments of Radiation
Oncology and Cell Biology, Kaplan Cancer Center, Rusk Building
Room 806, New York University School of Medicine, 400 East 34th
St., New York, NY 10016. Tel.: (212) 263-3021. Fax: (212) 263-3018.
E-mail: peter.brooks@med.nyu.edu
 
*Abbreviations used in this paper: CAM, chorioallantoic membrane; ECM,
extracellular matrix; HUVEC, human umbilical vein endothelial cell;
MMP, matrix metalloproteinase; SCID, severe combined immunodeficient.
Key words: angiogenesis; ECM; cryptic sites; tumor; migration 
1070 The Journal of Cell Biology 
 
|
 
 
 
Volume 154, 2001
 
shown to be specifically exposed within the subendothelial
basement membrane of angiogenic blood vessels, whereas lit-
tle if any was detected in association with quiescent vessels.
Importantly, our studies provide evidence that proteolytic ex-
posure of this cryptic site within collagen IV plays a functional
role in angiogenesis. In fact, a Mab HUIV26 directed to this
cryptic site potently inhibited angiogenesis and tumor growth
in multiple animal models. Together, these studies suggest a
novel mechanism by which proteolytic remodeling of the
ECM exposes cryptic protein sequences that promote novel
integrin–ligand interactions required for angiogenesis in vivo.
 
Results
 
Mab HUIV26 binds to a cryptic site within collagen IV
 
We sought to generate a Mab that would specifically recog-
nize proteolyzed or denatured collagen IV, but would not
recognize triple helical collagen IV. To produce this anti-
body, we used the technique of subtractive immunization in
conjunction with pepsin-solubilized human collagen IV (Xu
et al., 2000). Although pepsin-solubilized collagen IV is not
completely representative of native collagen IV found in
vivo, it does retain most of its triple helical structure. As
shown in Fig. 1 A, Mab HUIV26 specifically reacts with
thermally denatured collagen IV, while showing little if
any reactivity to triple helical collagen IV. Mab HUIV26
showed no reactivity to other ECM components, including
fibronectin, laminin, vitronectin, or fibrinogen. Impor-
tantly, Mab HUIV26 was shown to react with a cryptic site
within collagen type IV from a variety of species, including
human, mouse, chick, and rat (Xu et al., 2000). Moreover,
Mab HUIV26 did not react with denatured forms of col-
lagen I or the triple helical or denatured forms of other col-
lagens, including types II, III, or V (Xu et al., 2000).
Since angiogenesis is thought to be associated with pro-
teolytic remodeling, we examined whether matrix-degrading
enzymes had the capacity to expose the HUIV26 cryptic
epitope. Microtiter wells were coated with triple helical col-
lagen IV. Concentrated conditioned medium from human
umbilical vein endothelial cells (HUVECs), which contains
a variety of matrix-degrading enzymes, were added to the
wells. As shown in Fig. 1 B, HUVEC-conditioned medium
caused a time-dependent exposure of the HUIV26 cryptic
epitope. Importantly, incubation in the presence of the me-
talloproteinase inhibitor EDTA significantly inhibited the
exposure of the HUIV26 cryptic site. Moreover, addition of
exogenous, naturally occurring matrix metalloproteinase
(MMP) inhibitor TIMP-2 to the HUVEC condition me-
dium also reduced the exposure of the HUIV26 cryptic site
by 
 
 
 
30% (data not shown). Importantly, Mab HUIV26
does not react with any protein in the conditioned medium,
thus demonstrating the specificity of the results. Interest-
ingly, our recent studies involving retinal neovascularization
in MMP-9–deficient mice revealed an 
 
 
 
70–80% reduction
in the number of HUIV26 cryptic sites exposed per retina,
as compared with control wild-type mice (unpublished
data). Together, these findings provide evidence for a role
for MMPs in the exposure of the HUIV26 cryptic epitope.
The serine protease inhibitor aprotinin also reduced the ex-
posure of the cryptic epitope but was more effective at later
time points. However, a combination of both EDTA and
aprotinin caused a near complete inhibition of the exposure
of the HUIV26 cryptic site. Together, these findings suggest
that the HUIV26 cryptic site can be exposed by proteolytic
activity, which may include contributions from both MMPs
and serine proteases.
 
Exposure of the HUIV26 cryptic site within the 
subendothelial basement membranes of angiogenic 
blood vessels
 
We assessed whether the HUIV26 cryptic epitope could be
exposed within the basal lamina of blood vessels in vivo. Un-
fixed biopsy sections from normal human skin were incu-
bated with either activated or proMMP-2, HT1080 tumor–
conditioned medium, or control buffer. The tissues were
costained with Mab HUIV26 (green) and a polyclonal anti-
body directed to factor VIII–related antigen (red), a known
Figure 1. Mab HUIV26 reactivity with denatured/proteolyzed 
collagen IV in solid phase ELISA. Microtiter plates were coated with 
ECM components at a concentration of 25  g/ml. (A) Mab HUIV26 
was added (1  g/ml), followed 1 h later with goat anti–mouse 
peroxidase–labeled IgG. All data was corrected for nonspecific 
binding of secondary antibody. Data bars represent the mean 
OD   standard deviations from triplicate wells. (B) Microtiter
wells were coated with triple helical collagen IV at 25  g/ml. 
Concentrated (20 ) HUVEC serum–free–conditioned media was 
added to the wells in the presence or absence of EDTA, aprotinin, or 
both and allowed to incubate for 1, 6, and 24 h. The plates were 
next washed, blocked, and incubated with Mab HUIV26 or control 
antibody. All data was corrected for nonspecific secondary antibody 
binding. Data bars represent the mean OD   standard deviations 
from triplicate wells. 
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Figure 2. Exposure of the HUIV26 cryptic site 
within human tissue by proteolysis. Frozen 
sections of human tissue were mounted on glass 
slides. (A) Nonfixed normal human skin was 
incubated for 2 h with either control buffer, pro or 
activated MMP-2 (1.0  g/ml), or HT1080 tumor–
conditioned medium. The sections were costained 
with Mab HUIV26 and a polyclonal antibody 
directed to factor VIII–related antigen. Red indicates 
factor VIII staining of blood vessels, green indicates 
exposure of the HUIV26 cryptic epitope, and 
yellow indicates colocalization. Photo were taken 
at 630  under oil immersion (B) Normal human 
skin or malignant melanoma were costained with 
Mab HUIV26 and a polyclonal antibody directed 
to factor VIII–related antigen. Red indicates 
exposure of the HUIV26 cryptic site, green 
indicates human blood vessels, and yellow 
indicates colocalization. Photographs were taken 
at 200  magnification. (C) Representative 
example of human melanoma tumor tissue 
costained with Mab HUIV26 (green) and poly-
clonal antibody directed to factor VIII–related antigen (red), indicating that not all tumor vessels stain positive for HUIV26 epitope. Photos 
were taken at low power (200 ). (D) Normal human retinal tissue or retina from subjects with diabetic retinopathy were costained with Mab 
HUIV26 and a polyclonal antibody to factor VIII–related antigen. Green indicates human blood vessels and red indicates HUIV26 cryptic 
sites. Arrows indicate nonspecific fluorescence of retinal pigmented epithelium due to auto-fluorescence of lipofusion. Photomicrographs 
were taken at 200  magnification. Bars, 50.0  m.
 
marker of blood vessels. As shown in Fig. 2 A, blood vessels
(red) from normal human skin were readily detected. Little
if any of the cryptic HUIV26 epitope (green) was detected
within the vascular basement membranes or the surrounding
interstitial matrix from tissues treated with either inactive
proMMP-2 or control buffer (Fig. 2 A, top). In contrast, tis-
sues treated with either proteolytically active MMP-2 (Fig. 2
A, bottom left) or HT1080 tumor–conditioned medium
(Fig. 2 A, bottom right) demonstrated exposure of the
HUIV26 cryptic epitope, as indicated by colocalization (yel-
low) due to overlap of the exposed HUIV26 epitope (green)
and factor VIII–related antigen (red). Together, these find-
ings provide further evidence that the HUIV26 cryptic sites
could be exposed by proteolytic activity in a physiological
tissue.
To determine whether the HUIV26 cryptic site could also
be exposed during invasive cellular processes such as angio-
genesis and tumor growth in vivo, we examined biopsies
from normal human skin and malignant melanoma. As
shown in Fig. 2 B, left, blood vessels from normal human
skin showed little if any exposure of the HUIV26 cryptic
epitope (red). In contrast, the subendothelial basement
membrane of melanoma-associated (right) blood vessels
showed extensive expression of the HUIV26 cryptic site
(red). To estimate the relative percentage of tumor blood
vessels that were associated with the HUIV26 cryptic epi-
tope, costaining analysis for the expression of HUIV26 (red)
and factor VIII–related antigen (green) was performed on a
series of five melanoma tumor specimens. As shown in Fig.
2 C, although the HUIV26 cryptic epitope was detected in
association with numerous blood vessels, not all vessels
within a given field exhibited significant exposure of the
HUIV26 epitope. In fact, analysis of these tissue sections re-
vealed that an average of 
 
 
 
66% of the tumor-associated ves-
sels in any given field stained positive for the HUIV26
epitope (Table I). In similar experiments, we compared the
blood vessels from normal human retina to retinas from pa-
tients with diabetic retinopathy. As shown in Fig. 2 D, left,
normal retinal vessels showed little if any evidence of the
HUIV26 cryptic epitope. However, nonspecific auto fluo-
rescence from lipofucision (arrows) was detected within reti-
nal-pigmented epithelium (RPE), as has been described in
previous studies (Friedlander et al., 1996). In contrast, expo-
sure of the HUIV26 cryptic epitope (red) was readily de- 
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tected within the subendothelial basement membrane of an-
giogenic retinal blood vessels from patients with diabetic
retinopathy. Similar analysis of normal breast and bladder
tissue showed little if any evidence of the HUIV26 cryptic
site, whereas the subendothelial basement membranes of
blood vessels from both human breast and bladder tumors
stained positive (data not shown). Together, these results
suggest that the HUIV26 cryptic epitope may be an impor-
tant marker of angiogenic blood vessels in vivo.
 
Exposure of the HUIV26 cryptic epitope correlates 
with the expression and conversion of pro-MMP-2 to 
active MMP-2 in vivo
 
Our previous studies indicated that incubation of normal
human tissue with proteolytically active MMP-2, but not in-
active pro-MMP-2, can expose the HUIV26 cryptic site in
situ. Therefore, we examined whether the expression of
MMP-2 was associated with the exposure of the HUIV26
epitope during angiogenesis in vivo. To facilitate these stud-
ies, angiogenesis was induced within the chick chorioallan-
toic membrane (CAM) by either purified bFGF or a single
cell suspension of CS1 melanoma cells. CAM tissues were
costained with either Mab HUIV26 or a polyclonal anti-
body to MMP-2, or a polyclonal antibody directed to factor
VIII–related antigen. As shown in Fig. 3 A, top, MMP-2
(red) colocalized (yellow) with the cryptic HUIV26 epi-
tope (green) in blood vessels from either cytokine- or tu-
mor-induced angiogenesis. To confirm the exposure of the
HUIV26 cryptic epitope within the basement membrane of
blood vessels, similar CAM tissues were costained with poly-
clonal antibody directed to factor VIII–related antigen and
Mab HUIV26. As shown in Fig. 3 A, bottom, the HUIV26
cryptic epitope was associated with both bFGF-induced and
tumor-induced angiogenic blood vessels. To determine
 
Table I. 
 
Expression of HUIV26 cryptic epitope in human
melanoma vasculature
Tumor specimen
number
 Vessels positive
for HUIV26
 
%
 
16 4
27 4
35 0
47 8
56 5
10 (200
 
 
 
) microscopic fields were examined for each melanoma tumor
specimen. The percentage of HUIV26 staining vessels was estimated by
dividing by the total number of vessels per field that stained positive for
HUIV26 antigen and factor VIII–related antigen by the total number of
vessels per field (factor VIII–related antigen positive).
Figure 3. Exposure of the HUIV26 cryptic epitope is associated with the 
expression and activation of MMP-2 in vivo. bFGF-treated CAMs or CAMs 
containing CS1 melanoma tumors were costained with either Mab HUIV26 
and polyclonal anti–MMP-2 (top), or Mab HUIV26 and polyclonal antifactor 
VIII–related antigen (bottom). (A) Tissues were visualized by incubation with 
rhodamine- and FITC-conjugated secondary antibodies. Top, red indicates 
MMP-2 and green indicates HUIV26 cryptic epitope. Bottom, red indicates 
factor VIII staining of blood vessels, green indicates HUIV26 cryptic epitope, 
and yellow indicates colocalization. Photographs were taken at 200  
magnification. (B) CAMs of 10-d-old embryos were stimulated with bFGF 
and total CAM lysates were prepared at 2, 24, 48, and 72 h. Top, gelatin 
zymogram of total CAM lysates after stimulation with bFGF. Bottom, dot blot of total CAM lysates. Total collagen IV (triple helical and denatured) 
was detected with a polyclonal antibody to both native and denatured collagen IV. Denatured collagen IV was detected with Mab HUIV26. (C) 
Microtiter plates were coated with triple helical collagen type IV (25  g/ml). MMP-2 (500 ng/ml), tPA (6 U/ml, specific activity 700  g/mg pro-
tein), or NT (control buffer) were incubated for 18 h. The wells were washed, blocked with BSA, and the HUIV26 cryptic sites were detected with 
Mab HUIV26 (1.0  g/ml). Data bars represent the mean OD   standard deviations from triplicate wells. Bars, 50.0  m. 
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whether the proteolytically active form of MMP-2 corre-
lated with exposure of the HUIV26 cryptic epitope, tissue
lysates were prepared from these CAMs after bFGF stimula-
tion and analyzed by both gelatin zymography and dot blot
analysis. As shown in Fig. 3 B, top, bFGF treatment was as-
sociated with a time-dependent conversion of the latent 72-
kD MMP-2 to its proteolytically active 62-kD species be-
tween 24 and 48 h after stimulation. These findings were
consistent with our previously published results (Brooks et
al., 1996). The gelatinolytic bands were confirmed to be pro
(72 kD) and active (62 kD) MMP-2 by Western blot analy-
sis (data not shown). Interestingly, dot blot analysis of these
same lysates demonstrated the generation of the HUIV26
epitope between 24 and 48 h which correlated directly with
the bFGF-associated activation of MMP-2. To confirm that
activated MMP-2 can contribute to the exposure of the
HUIV26 epitope, in vitro ELISA assays were conducted.
Triple helical collagen type IV was coated on microtiter
wells as described above. The wells were next incubated with
either activated MMP-2, the serine protease tPA, or control
buffer for 18 h. The wells were washed and the HUIV26
cryptic epitope was detected with Mab HUIV26. As shown
in Fig. 3 C, incubation of triple helical collagen type IV with
activated MMP-2 caused an approximately threefold in-
crease in the exposure of the HUIV26 epitope as compared
with either no treatment (control buffer), or the serine pro-
tease tPA. These findings provide further evidence that
MMPs such as MMP-2 may contribute to the exposure of
the HUIV26 epitope. However, these results do not rule out
the likely contributions of other MMPs or serine proteases
in the exposure of the HUIV26 cryptic site in vivo. Since
MMP-9, the second major MMP capable of cleaving triple
helical collagen IV, was not detected in the CAM lysates,
 
it is likely, but not direct proof, that MMP-2 is at least
one protease that may contribute to the generation of the
HUIV26 epitope in the chick embryo model.
 
Mab HUIV26 potently inhibits angiogenesis in vivo
 
Previous studies indicated that MMP-2–mediated proteoly-
sis of collagen IV within the basement membrane prepara-
tion Matrigel resulted in enhanced endothelial cord forma-
tion (Schnaper et al., 1993). Moreover, our studies indicate
that the HUIV26 cryptic site can be exposed after thermal
denaturation of Matrigel (data not shown). Together, these
findings suggest that cellular interactions with the HUIV26
cryptic epitope may facilitate angiogenesis. To examine this
possibility, we analyzed the effects of Mab HUIV26 in the
rat corneal micropocket assay (Dipietro et al., 1998). Hy-
dron pellets containing either bFGF alone, bFGF plus
HUIV26, or bFGF plus an isotype-matched control anti-
body were surgically implanted into the corneas of rats
(Dipietro et al., 1998). After a 5-d incubation period, cor-
neal angiogenesis was quantified (Koch et al., 1995). As
shown in Fig. 4 A, bFGF induced a strong angiogenic re-
sponse in the rat corneas (top). In contrast, little angio-
genesis was detected in the corneas implanted with bFGF
hydron pellets containing Mab HUIV26 (middle), as com-
pared with either no treatment or treated with an isotype-
matched control antibody (top and bottom). In fact, as
shown in Fig. 4 B, rat corneal angiogenesis was inhibited by
 
 
 
70% as compared with controls (
 
P 
 
 
 
 0.001). Similar re-
sults were observed with bFGF- or VEGF-induced angio-
genesis within the chick CAM model (data not shown).
These findings provide evidence for a potent inhibitory ac-
tivity for Mab HUIV26 on cytokine-induced angiogenesis
in vivo.
Figure 4. Effects of purified Mab HUIV26 on angiogenesis in 
vivo. Rat corneal micropocket assays were performed to assess the 
effects of Mab HUIV26 on angiogenesis. (A) Representative 
corneas from rats implanted with hydron pellets containing bFGF 
(top), bFGF   Mab HUIV26 (middle) or bFGF   control Mab 
(bottom). Black arrows indicate angiogenic neovessels. Red arrows 
indicate preexisting limbal vessels. (B) Quantification of the area 
of neovascularization within rat corneas. Data bars represent the mean area of neovascularization from the limbus to hydron pellet. 
Experiments were performed at least twice with five to seven eyes per condition. 
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Systemic administration of Mab HUIV26 potently 
inhibits tumor growth in vivo
 
The growth of most all solid tumors is thought to depend
on angiogenesis (Weidner et al., 1991, 1992). Therefore,
we evaluated its effects on the growth of tumors of distinct
histological origin within two independent animal models.
First, CS1 melanoma or HT1080 human fibrosarcoma
cells were applied to the CAMs of 10-d-old chick embryos
(Brooks et al., 1996). 24 h latter, the embryos were treated
systemically with a single injection (100 
 
 
 
g/embryo) of ei-
ther Mab HUIV26 or an isotype-matched control anti-
body. As shown in Fig. 5, A and B, Mab HUIV26 inhib-
ited HT1080 and CS1 tumor growth by 50 and 80%,
respectively. Treatment of these embryos with either an ir-
relevant isotype-matched control antibody or an antibody
directed to the ECM protein fibronectin showed little if
any effect.
To confirm these findings in a second animal model, we
examined the effects of Mab HUIV26 on M21 human mel-
anoma tumor growth in severe combined immunodeficient
(SCID) mice. M21 human melanoma cells (2 
 
  
 
10
 
6
 
)
were injected subcutaneously in SCID mice. 3 d later the
mice were treated with daily i.p. injections of either Mab
HUIV26 or isotype-matched control antibody (100 
 
 
 
g/
mouse). As shown in Fig. 5 C, mice from either untreated or
treated with an irrelevant isotype-matched control antibody
formed tumors of similar size. In contrast, M21 tumor
growth in mice treated with Mab HUIV26 were inhibited
by 80 to 90% as compared with controls. These findings
confirm the potent antitumor activity of Mab HUIV26 and
demonstrate that this activity is not limited to a single tumor
type or animal model.
 
Mab HUIV26 inhibits human endothelial cell adhesion 
and migration on denatured, but not triple helical, 
collagen IV
 
It is possible that exposure of the HUIV26 cryptic epitope
may contribute to angiogenesis in part by regulating endo-
thelial cell–integrin interactions. To examine this possibility,
we evaluated the effects of Mab HUIV26 on human endo-
thelial cell adhesion to either triple helical or denatured hu-
man collagen IV. HUVECs were allowed to attach to im-
mobilized triple helical or denatured collagen IV in the
presence or absence of Mab HUIV26 or isotype-matched
control antibody (50 
 
 
 
g/ml). As shown if Fig. 6 A, HU-
VECs readily attached to both triple helical and denatured
collagen IV. In contrast, HUVEC adhesion to denatured
collagen IV was inhibited by 
 
 
 
60% in the presence of Mab
HUIV26, while having little if any effect on adhesion to tri-
ple helical collagen IV. An isotype-matched control anti-
body had no effect of cell adhesion to either triple helical or
denatured collagen IV.
In similar experiments, we examined the effects of Mab
HUIV26 on HUVEC migration in vitro. Membranes from
Transwell™ migration chambers were coated with either
triple helical or denatured collagen IV. HUVECs were re-
suspended in migration buffer in the presence or absence of
Mab HUIV26 or an isotype-matched control antibody (50
 
 
 
g/ml). As shown in Fig. 6 B, Mab HUIV26 had little if
Figure 5. Effects of systemic administration of purified Mab 
HUIV26 on tumor growth in vivo. The effects of Mab HUIV26 on 
tumor growth was assessed in two independent models, including 
the chick embryo (A and B) and the SCID Mouse (C). HT1080 
human fibrosarcoma cells (4   10
5) or CS-1 melanoma tumor cells 
(5   10
6) were inoculated on the CAMs of 10-d-old chick embryos. 
24 h later, the embryos received a single intravenous injection of 
100  g of Mab HUIV26 or isotype-matched control. (A) Quantitation 
of HT1080 tumor growth in the chick embryo. (B) Quantitation of 
CS-1 tumor growth within the chick embryo. Data bars represent 
the mean tumor weights   the standard errors from 5 to 10 embryos 
per condition. (C) SCID mice were injected subcutaneously with
2   10
6 M21 human melanoma cells. 3 d later mice were treated 
i.p. daily for 24 d with 100  g of either Mab HUIV26 or an isotype-
matched control antibody. Tumor size was monitored with calipers 
and tumor volumes were determined. Data represents the mean   
standard errors of the tumor volumes. All experiments were 
conducted 3 to 4 times with 5 to 10 animals per condition. 
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any effect on HUVEC migration or triple helical collagen,
but inhibited migration by 
 
 
 
70% on denatured collagen
IV. HUVEC migration was not effected by an isotype-
matched control antibody. These findings suggest a poten-
tial mechanism by which Mab HUIV26 may disrupt an-
giogenesis by inhibiting endothelial cell interactions with
the HUIV26 cryptic epitope, thereby disrupting adhesion
and migration.
 
Mab HUIV26 inhibits purified integrin 
 
 
 
v
 
 
 
3 binding to 
denatured collagen IV
 
We sought to determine whether an integrin receptor
was involved in mediating cellular interactions with the
HUIV26 cryptic epitope. To facilitate these studies, microti-
ter wells were coated with either triple helical or denatured
collagen IV. The wells were incubated with purified integrin
receptors, including 
 
 
 
1
 
 
 
1, 
 
 
 
2
 
 
 
1, 
 
 
 
v
 
 
 
3, and 
 
 
 
5
 
 
 
1. After
incubation, bound integrins were detected with antiintegrin-
specific antibodies. As shown in Fig. 7 A, the collagen-bind-
ing integrins 
 
 
 
1
 
 
 
1 and 
 
 
 
2
 
 
 
1 bound to triple helical col-
lagen in a dose-responsive manner, whereas integrins 
 
 
 
v
 
 
 
3
and 
 
 
 
5
 
 
 
1 showed little if any interaction. After denatur-
ation, 
 
 
 
1
 
 
 
1 binding was lost; however, denatured collagen
IV acquired the capacity to bind to integrin 
 
 
 
v
 
 
 
3 (Fig. 7 B).
Moreover, denatured collagen IV retained its ability to bind
to 
 
 
 
2
 
 
 
1, whereas the control fibronectin receptor integrin
 
 
 
5
 
 1 failed to interact (Fig. 7 B). These findings suggest
that denaturation of the triple helical structure of collagen
IV can shift integrin binding specificity from that of a  1
dependency to both  1 and  v 3. To determine whether
integrin  2 1 or integrin  v 3 interacts with the HUIV26
cryptic epitope, similar receptor binding assays were per-
formed in the presence or absence of Mab HUIV26 or an
isotype-matched control antibody. As shown in Fig. 7 C,
Mab HUIV26 failed to block the ability of purified integrin
 2 1 to bind to denatured collagen IV, while inhibiting in-
tegrin  v 3 binding by  70%. Together, these findings
suggest that integrin  v 3 may function as a receptor for
the HUIV26 cryptic epitope.
It is known that the tripeptide sequence RGD is recog-
nized by integrin  v 3 (Smith and Cheresh, 1988). Col-
lagen IV has 11 different RGD-containing sites, which ap-
pear to be cryptic since integrin  v 3 fails to bind to triple
helical collagen IV. Therefore, it is possible that one or more
of these RGD sequences may represent the HUIV26 cryptic
epitope. To examine this possibility, we synthesized 10-mer
peptides corresponding to all 11 distinct RGD sites within
collagen IV. Integrin  v 3 could bind to all 11 RGD pep-
tides, yet none of the RGD peptides were recognized by Mab
HUIV26. Moreover, none of the 11 peptides were capable of
blocking Mab HUIV26 binding to denatured collagen IV
(data not shown). Although these findings do not completely
rule out the possibility that an RGD sequence is associated
with the HUIV26 cryptic site, they do suggest that RGD se-
quences within collagen IV are not sufficient to support in-
teractions with Mab HUIV26 and that other protein se-
quences are critical for Mab HUIV26 recognition of its
epitope. Further studies are now under way to more precisely
identify the amino acid sequence of the HUIV26 cryptic site.
Discussion
Angiogenesis plays a critical role in the normal development
as well as the spread of tumors to distant sites (Risau and
Lemmon, 1988; Brooks et al., 1994; Hanahan and Folk-
man, 1996). Several elegant studies have demonstrated the
importance of numerous families of molecules in the regula-
tion of angiogenesis (Blood and Zetter, 1990; Rak et al.,
1995; Suri et al., 1996). The majority of these studies have
focused on growth factors and their receptors, cell adhesion
molecules, and matrix-degrading proteases (Liotta et al.,
1991; O’Reilly et al., 1994; Brooks et al., 1996; Vu et al.,
1998). In comparison, relatively little emphasis has been
placed on the ECM as a potential therapeutic target to regu-
late neovascularization.
Figure 6. Effects of Mab HUIV26 on human endothelial cell 
adhesion and migration. Microtiter plates (96 wells) and Transwell 
membranes were coated with triple helical or denatured colla-
gen type IV (25  g/ml). (A) Subconfluent HUVECs (10
5) were 
resuspended in adhesion buffer and allowed to attach in the 
presence or absence of Mab HUIV26 or an isotype-matched control 
antibody for 30 min. Nonattached cells were removed by washing 
and the attached cells were stained with crystal violet. (B) Subcon-
fluent HUVECs (10
5) were resuspended in migration buffer and 
allowed to migrate in the presence or absence of Mab HUIV26 or 
an isotype-matched control antibody. Cells remaining on the top 
side of the membrane were removed and cells that had migrated to 
the under side were stained with crystal violet. Cell adhesion and 
migration was quantified by measuring the OD of eluted dye at 
600 nm. Data bars represent the mean OD   standard deviation 
from triplicate wells expressed as a percentage of control.1076 The Journal of Cell Biology | Volume 154, 2001
Recent studies have indicated that proteolytic enzymes,
such as members of the MMP family, play an important role
in angiogenesis (Hiraoka et al., 1998; Stetler-Stevenson,
1999; Werb et al., 1999). In fact, mice deficient in MMP-2
or MMP-9 exhibit reduced angiogenesis in vivo (Itoh et al.,
1998; Vu et al., 1998). Moreover, our recent studies suggest
that MMP-9–deficient mice exhibit reduced exposure of the
HUIV26 sites within the retina during hypoxia-induced ret-
inal neovascularization in vivo (unpublished data). To-
gether, these findings suggest that proteolysis of collagen, as
well as perhaps other ECM proteins, is of critical importance
in angiogenesis. Although soluble fragments of collagen have
been detected in the circulation, little if any direct evidence
is available that proteolyzed matrix–associated forms of col-
lagen IV exist within the subendothelial basement mem-
brane or that they play a functional role in angiogenesis
(Jukkola et al., 1997). Here, we describe the use of a unique
Mab that specifically binds to proteolyzed and denatured
collagen IV, but does not react with triple helical collagen
IV. This cryptic HUIV26 epitope was shown to be specifi-
cally exposed within the subendothelial basement membrane
of angiogenic and tumor-associated blood vessels, but not
within the basement membrane of normal vessels. The high
degree of specificity for angiogenic and tumor vessels is
likely due to the slow turnover of members of the collagen
family in healthy tissues as compared with the rapid remod-
eling that likely occurs during angiogenesis.
Recent evidence suggests that cellular interactions with
proteolyzed forms of ECM molecules such as osteopontin,
and laminin may result in altered cellular behavior including
changes in cell motility (Senger and Perruzzi, 1996; Gian-
nelli et al., 1997; Davis et al., 2000). Thus, proteolytic cleav-
age of ECM proteins, together with cell surface receptor
binding events, may represent a previously unappreciated
mechanism to transmit cryptic regulatory signals that are re-
quired for angiogenesis. Consistent with this hypothesis, we
provide evidence that a Mab directed to the matrix-immobi-
lized HUIV26 cryptic site potently inhibits angiogenesis in
multiple animal models. Importantly, angiogenesis was in-
hibited irregardless of the cytokine used or the animal spe-
cies in which these assays were conducted. Moreover,
systemic administration of Mab HUIV26 also potently in-
hibited the growth of several tumor types of distinct histo-
logical origin. Interestingly, the exposure of the HUIV26
epitope was associated with a loss of  1 1 binding and a
gain in  v 3 binding, whereas  2 1-mediated interactions
were unaffected. This shift in integrin binding may initiate a
unique signaling cascade required for angiogenesis in vivo.
Importantly, recent studies have indicated that MMP-
mediated cleavage of laminin 5 can expose a cryptic epitope
which potentiates tumor cell motility in vitro (Giannelli et
al., 1997). Moreover, proteolytic cleavage of fibronectin and
osteopontin also enhance cellular migration in vitro (Bower-
sox and Sorgenete, 1982; Senger and Perruzzi, 1996). How-
ever, little is known concerning the roles that these proteo-
lyzed ECM proteins may have on pathological processes in
vivo. Here, we provide evidence for the first time that pro-
teolytic exposure of the HUIV26 cryptic site is required for
angiogenesis and tumor growth in vivo. Moreover, our results
suggest that proteolytic remodeling is not solely a mechanism
Figure 7. Integrin binding to triple helical and denatured human 
collagen IV. Microtiter wells were coated with either triple helical or 
denatured human collagen IV (25  g/ml). Purified human integrins 
 1 1,  2 1,  5 1, or  v 3 (0.5–4  g/ml) were allowed to bind to 
triple helical collagen IV (A) or denatured collagen IV (B) for 1 h at 
37 C. Integrin binding was detected with antiintegrin antibodies. (C) 
Purified human integrins  2 1 and  v 3 (1.0  g/ml) were allowed 
to bind to denatured collagen IV–coated plates for 1 h at 37 C in the 
presence or absence of Mab HUIV26 or an isotype-matched control 
antibody. Integrin binding was detected by incubation with either 
polyclonal antibody directed to  2 or  3 integrins. Data bars 
represent the mean OD   standard deviations from triplicate wells.Cryptic site of collagen IV in angiogenesis | Xu et al. 1077
to destroy physical barriers that obstruct vascular cell migra-
tion, but can expose cryptic sites that are essential for the an-
giogenic process. In fact, our systematic search for cryptic
sites in other ECM proteins have resulted in the generation of
several distinct Mab directed to different cryptic epitopes
which potently inhibit angiogenesis and tumor growth (un-
published data). Thus, an in depth knowledge of the roles
these cryptic sites play in angiogenesis is critical to our un-
derstanding of blood vessel formation. Together, our find-
ings indicate that targeting matrix-immobilized cryptic sites
within ECM molecules may be a highly specific and powerful
new approach for the treatment of neoplastic diseases.
Materials and methods
Antibodies and reagents
Mab HUIV26 directed to a cryptic site within collagen IV was generated
by subtractive immunization (Xu et al., 2000). The immunogen used for
the production of Mab HUIV26 was thermally denatured, pepsin-solubi-
lized human collagen IV from Sigma-Aldrich. Mab HUIV26 recognizes a
cryptic epitope within collagen IV from a variety of species, including hu-
man, chick, rat, and mouse, but does not react with triple helical collagen
IV. Mab LM609 (anti- v 3) and vitronectin were gifts from Dr. David
Cheresh (Scripps Research Institute, La Jolla, CA). Antifactor VIII–related
antigen polyclonal antibody was obtained from BioGenex. Antifibronectin
Mab and normal mouse isotype–matched control antibodies were ob-
tained from Sigma-Aldrich. Mabs 1973 (anti- 1), 1950 (anti- 2), 1928
(anti- 5), and polyclonal antibodies AB769 (anticollagen IV) and AB809
(anti–MMP-2) were obtained from Chemicon International. FITC- and
rhodamine-conjugated secondary antibodies were from BioSourse Interna-
tional. Purified ECM molecules, fibronectin, laminin, fibrinogen, collagen
I, and collagen IV were obtained from Sigma-Aldrich. Purified MMP-2 was
obtained from Chemicon International. OCT-embedding compound was
from VWR Scientific Products. Purified integrins  1 1,  v 3, and  5 1
were obtained from Chemicon International. Integrin  2 1 was purified
from platelets as described previously (Davis, 1992).
Cells and cell culture
Human melanoma cell line M21 was a gift from Dr. David Cheresh
(Scripps Research Institute, La Jolla, CA). CS1 hamster melanoma cells
were provided by Dr. C. Damsky (University of California, San Francisco,
CA). Human Fibrosarcoma cell line HT1080 was obtained from the Amer-
ican Type Culture Collection. Cell lines were maintained in RPMI 1640
supplemented with 10% FBS, 2 mM L-glutamine, and Pen-Strep. HUVECs
were obtained from Clonectics Corp. and were maintained in M199 me-
dium containing 20% FBS, 100  g/ml gentamicin, 4 mM L-glutamine, 0.9
mg/ml heparin, and 30  g/ml ECGS (Upstate Biotechnology).
Solid phase ELISA
Nontissue culture–treated 96-well ELISA plates were coated (50  l/well)
with ECM proteins (25  g/ml in PBS) for 18 h at 4 C. Plates were blocked
with 100  l/well of 1.0% BSA in PBS for 1 h at 37 C. Purified Mab HUIV26
(1.0  g/ml) was diluted in 1.0% BSA in PBS (100  l/well). Plates were incu-
bated for 1 h at 37 C and washed three times with PBS. Goat anti–mouse
peroxidase–conjugated IgG was added and allowed to incubate for 1 h at
37 C. The plates were washed three times with PBS and ELISA substrate
(OPD) was added and the OD was measured with an ELISA plate reader at
a wavelength of 490 nm. All measurements were corrected for nonspecific
binding to BSA and reactivity of secondary antibody.
For proteolyzed collagen IV ELISAs, microtiter plates were coated as de-
scribed above with collagen IV. Concentrated (20 ) HUVEC serum-free–
conditioned medium (100  l/well) with or without EDTA (50 mM) or apro-
tinin (10  g/ml) was incubated for 1, 6, and 24 h at 37 C. At each time
point, the wells were washed five times with PBS/EDTA and blocked with
1.0% BSA. No significant loss of total bound collagen IV was noted be-
tween experimental conditions, as detected by control incubations with
polyclonal antibodies directed to collagen IV. Detection of Mab HUIV26
immunoreactivity was performed as described above.
Immunofluorescence analysis of tissue sections
Human and chick tissues were embedded in OCT and snap frozen in liq-
uid nitrogen (Brooks et al., 1996). In brief, 4-um sections of normal human
skin, retina, and chick CAM, or human malignant melanoma or retina from
patients with diabetic retinopathy were fixed by incubation for 30 s in 50%
methanol/50% acetone. Tissue were blocked by incubation with 2.5%
BSA in PBS followed by incubation with primary antibodies HUIV26 (100
 g/ml), anti-MMP-2 (50  g/ml), or polyclonal antifactor VIII (1:100 dilu-
tion) in 1.0% BSA in PBS for 2 h at 37 C. In control experiments, tissues
were incubated with secondary antibodies only. Tissue were washed five
times in PBS for 5 min each followed by incubation with FITC- and
rhodamine-conjugated secondary antibodies (1:400 dilution in 1.0% BSA
in PBS) for 1 h at 37 C. In experiments in which the tissues were proteo-
lyzed before staining, unfixed frozen sections were incubated with either
control buffer alone (50 mM Tris, 200 mM NaCl, 10 mM CaCl2, pH 7.5),
activated or Pro MMP-2 (1.0  g/ml), or concentrated (20 ) serum–free
HT1080–conditioned medium for 2 h at 37 C. The tissues were then
washed extensively five times with PBS. Costaining with primary antibod-
ies was carried out as described above. Photomicrographs were taken at
either low (200 ) or high power (630 ).
Quantitation of HUIV26-positive tumor blood vessels
To assess the relative percentage of HUIV26-positive tumor blood vessels,
costain analysis was performed on frozen sections of human melanoma tu-
mor biopsies. In brief, 4.0-um tissue sections were cut from frozen blocks
of human malignant melanoma tumors. The tissues were costained with
Mab HUIV26 and a polyclonal antibody directed to factor VIII–related an-
tigen. 10 sections were analyzed for each of 5 distinct tumors. For each tu-
mor, the percentage of HUIV26-positive vessels were estimated by deter-
mining the number of tumor vessels that costained for both HUIV26- and
factor VIII–related antigen, as compared with the vessels that only stained
positive for factor VIII–related antigen. These observations were conducted
using low power magnification (200 ).
Gelatin zymography and dot blot analysis
Angiogenesis was induced within the CAMs of 10-d-old chick embryos by
placing a filter disc saturated with bFGF (25  l) at 1.0  g/ml (Brooks et al.,
1998). Tissue directly beneath the filter discs were harvested at 2, 24, 48,
and 72 h after addition of the bFGF. CAM tissues were homogenized in ly-
sis buffer containing 1.0% TX-100, 50 mM Tris, 300 mM NaCl, pH 7.5. 20
 g of total CAM lysate were electrophoresed through a 10% SDS-PAGE
gel polymerized with 0.2% gelatin (Brooks et al., 1996). Gels were washed
three times for 1 h each with 2.5% TX-100 and incubated for 16 h at 37 C
in collagenase buffer containing 50 mM TRIS, 200 mM NaCl, and 10 mM
CaCl2, pH 7.5. Gelatinolytic activity was visualized by staining with 0.5%
Coomassie blue. Gelatinolytic bands were confirmed to be pro and active
MMP-2 by Western blot analysis with anti-MMP-2–specific Mab.
In dot blot analysis, 10  g of total protein was spotted (10  l/spot) on
nitrocellulose paper. Blots were incubated in 10% milk diluted in TBS-T to
block nonspecific binding and incubated with either anticollagen IV poly-
clonal antibody or Mab HUIV26 (1.0  g/ml). Blots were next washed and
incubated with peroxidase-labeled secondary antibodies. Immunoreactive
bands were visualized by enhanced chemiluminescence according to the
manufacture’s instructions.
Rat corneal micropocket angiogenesis assay
The rat corneal micropocket angiogenesis assay was performed essentially
as described (Koch et al., 1995; Dipietro et al., 1998). In brief, hydron pel-
lets (Polyhydroxyethyl methacrylate; Interferon Sciences) were prepared
containing 1.2  l of saline, 1.2  l of bFGF, either Mab HUIV26 or control
Ab (50  g), and 12  l of 12% hydron in ethanol. Mixtures were applied to
a 1.5-mm diameter Teflon rod (Dupont). The hydron pellets were dried in
a laminar flow hood. Pockets were cut in the corneal stroma of F344 fe-
male rats, 1.5-mm from the limbus and the Hydron pellets implanted
(Koch et al., 1995; Dipietro et al., 1998). Corneas were routinely examined
by slit-lamp biomicroscopy for up to 5 d. Corneas were photographed on
day 5 after implantation. Rats were anesthetized and perfused with saline
followed by colloidal carbon to enhance visualization of blood vessels.
The corneas were dissected, fixed in 4% paraformaldehyde, and mounted
on glass slides in 50% glycerol/50% gelatin solution. Corneal neovascular-
ization was quantified by measuring the area of neovascularization from
the limbus to the pellet. The area of neovascularization was acquired with
Image Pro Plus 3.0 software (Media Cybernetics). Experiments were con-
ducted two to three times with five to seven eyes per condition.
Chick embryo tumor growth assays
Single cell suspensions of CS1 melanoma (5   10
6 per embryo) or HT1080
fibrosarcoma (4   10
5 per embryo) were applied in a total volume of 40  l
of RPMI to the CAMs of 10-d-old embryos (Brooks et al., 1998). 24 h later,1078 The Journal of Cell Biology | Volume 154, 2001
the embryos received a single intravenous injection of purified Mabs
HUIV26 or control Mabs (100  g per embryo). Tumors were grown for
7 d, then resected and wet weights were determined. Experiments were
performed three to four times with five to ten embryos per condition.
SCID mouse tumor growth assay
Subconfluent human M21 melanoma cells were harvested, washed, and
resuspended in sterile PBS (20   10
6 per ml). SCID mice were injected
subcutaneously with 100  l of M21 human melanoma cell (2   10
6) sus-
pension. 3 d after tumor cell injection, mice were either untreated or
treated i.p. (100  g/ mouse) with either Mab HUIV26 or an isotype-
matched control antibody. The mice were treated daily for 24 d. Tumor
size was measured with calipers and the volume was estimated using the
formula V   L
2   W/2, where V is equal to the volume, L is equal to the
length, and W is equal to the width. Experiments were completed three
times with similar results
Cell adhesion assays
Human collagen type IV (triple helical or denatured) was immobilized (25
 g/ml) on 48-well nontissue culture–treated plates. Wells were washed
and incubated with 1% BSA in PBS for 1 h at 37 C. Subconfluent HUVECs
were harvested, washed, and resuspended in adhesion buffer containing
RPMI 1640, 1 mM MgCl2, 0.2 mM MnCl2, and 0.5% BSA. HUVECs (10
5)
were resuspended in 200  l of the adhesion buffer in the presence or ab-
sence of Mab HUIV26 or control antibodies (50  g/ml) and were added to
each well and allowed to attach for 30 min at 37 C. The nonattached cells
were removed and the attached cells were stained for 10 min with crystal
violet as described (Petitclerc et al., 1999). The wells were washed three
times with PBS and cell-associated crystal violet was eluted by addition of
100  l of 10% acetic acid. Cell adhesion was quantified by measuring the
optical density of eluted crystal violet at a wavelength of 600 nm.
Cell migration assays
Transwells membranes (8.0- m pore size) were coated with human col-
lagen type IV (triple helical or denatured) for 16 h at 4 C. Next, 600  l of
migration buffer (RPMI 1640, 1 mM MgCl2, 0.2 mM MnCl2, and 0.5% BSA)
was added to the lower chamber. HUVECs (10
5) were resuspended in mi-
gration buffer in the presence or absence of Mab HUIV26 or control anti-
bodies (50  g/ml) and added to upper chamber and allowed to migrate for
5 h at 37 C. Cells remaining on the top of the membrane were removed and
cells that had migrated to the underside were fixed and stained with crystal
violet. The membranes were washed and the cell-associated crystal violet
was eluted with 10% acetic acid. Cell migration was quantified by measur-
ing the optical density of eluted crystal violet at a wavelength of 600 nm.
Purified integrin receptor binding assays
ELISA plates (96 well) were coated with either 25  g/ml of denatured or tri-
ple helical collagen IV for 18 h at 4 C. Plates were washed three times
with 200  l of PBS and blocked with 100  l/well of 1.0% BSA in PBS for
1 h at 37 C. Purified human integrin receptors ( 1 1,  2 1,  5 1, and
 v 3) were diluted in binding buffer containing 20 mM Tris, 150 mM
NaCl, 1 mM MgCl2, 0.2 mM MnCl2, 0.5% BSA, pH 7.5. Integrins (0.5–4.0
 g/ml) were allowed to bind for 1 h at 37 C. Next, the plates were washed
three times with binding buffer and incubated with antiintegrin specific
Mabs. The plates were washed three times with PBS and incubated with
goat anti–mouse peroxidase–conjugated IgG for 1 h at 37 C. The plates
were washed three times with PBS and ELISA substrate (OPD) was added
and the OD was measured with an ELISA plate reader at a wavelength of
490 nm. All measurements were corrected for nonspecific binding to BSA
and for reactivity with secondary antibody.
Statistical analysis
Statistical analysis was performed using Student’s t test. P values  0.05
were considered significant.
The authors would like to thank Kathryn Carner for her help in the prepara-
tion of this manuscript and Dr. Daniel Broek for his critical reading and
helpful suggestions.
P.C. Brooks was supported by grants CA74132 and CA086140, and
G.E. Davis was supported by grant HL 59971 from the National Institutes
of Health (NCH/NCI).
Received: 26 March 2001
Revised: 6 July 2001
Accepted: 13 July 2001
References
Blood, C.H., and B.R. Zetter. 1990. Functional interactions with the vasculature:
angiogenesis and tumor metastasis. Biochim. Biophys. Acta. 1032:89–118.
Bowersox, J.C., and N. Sorgenete. 1982. Chemotaxis of aortic endothelial cells in
response to fibronectin. Cancer Res. 42:2547–2551.
Brooks, P.C., A.M.P. Montgomery, M. Rosenfeld, R.A. Reisfeld, T. Hu, G. Klier,
and D.A. Cheresh. 1994. Integrin  v 3 antagonists promote tumor regres-
sion by inducing apoptosis of angiogenic blood vessels. Cell. 79:1157–1164.
Brooks, P.C., S. Stromblad, L.C. Sanders, T.L. von Schalscha, R.T. Aimes, W.G.
Stetler-Stevenson, J.P. Quigley, and D.A. Cheresh. 1996. Localization of
matrix metalloproteinase MMP-2 to the surface of invasive cells by interac-
tion with integrin. Cell. 85:683–693.
Brooks, P.C., A.M.P. Montgomery, and D.A. Cheresh. 1998. Use of the 10 day
old chick embryo model for studying angiogenesis. A.R. Howlett, editor.
Humana Press Inc., Totowa, NJ. 257–269.
Davis, G.E. 1992. Affinity of integrins for damaged extracellular matrix:  v 3
binds to denatured collagen type I through RGD sites. Biochem. Biophys.
Res. Commun. 182:1025–1031.
Davis, G.E., K.J. Bayless, M.J. Davis, and G.A. Meinirger. 2000. Regulation of tis-
sue injury responses by the exposure of matricryptic sites within extracellular
matrix molecules. Am. J. Pathol. 156:1489–1498.
Dipietro, L.A., M. Burdick, Q.E. Low, S.L. Kunkel, and R.M. Strieter. 1998.
MIP-1  as a critical macrophage chemoattractant in murine wound repair.
J. Clin. Invest. 101:1693–1698.
Dogic, D., B. Eckes, and M. Aumailley. 1999. Extracellular matrix, integrins and
focal adhesions. Curr. Top. Pathol. 93:75–83.
Emsley, J., G. Knight, R.W. Frarndale, M.J. Barnes, and R.C. Liddington. 2000.
Structural basis of collagen recognition by integrin  2 1. Cell. 100:47–56.
Friedlander, M., C.L. Theesefeld, M. Sugita, M. Fruttiger, M.A. Thomas, S.
Change, and D.A. Cheresh. 1996. Involvement of integrins  v 3 and  v 5
in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA. 93:9764–9769.
Giannelli, G., J. Falk-Marzillier, O. Schiraldi, W.G. Stetler-Stevenson, and V.
Quaranta. 1997. Induction of cell migration by matrix metalloproteinase-2
cleavage of laminin-5. Science. 277:225–228.
Hanahan, D., and J. Folkman. 1996. J. Patterns and emerging mechanisms of the
angiogenic switch during tumorigenesis. Cell. 86:353–364.
Herbst, T.J., J.B. McCarthy, E.C. Tsilbary, and L.T. Furcht. 1998. Differential ef-
fects of laminin, intact type IV collagen, and specific domains of type IV col-
lagen on endothelial cell adhesion and migration. J. Cell Biol. 106:1365–
1373.
Hiraoka, N., E. Allen, I.J. Apel, M.R. Gyetko, and S.J. Weiss. 1998. Matrix metal-
loproteinases regulate neovascularization by acting as pericellular fibrino-
lysins. Cell. 95:365–377.
Hudson, B.G., S.T. Reeders, and K.J. Tryggvason. 1993. Type IV collagen: struc-
ture, gene organization, and role in human diseases. J. Biol. Chem. 268:
26033–26036.
Itoh, T., M. Tanioka, H. Yoshida, T. Yoshioka, H. Nishimoto, and S. Itohara.
1998. Reduced angiogenesis and tumor progression in gelatinase A-deficient
mice. Cancer Res. 58:1048–1051.
Jukkola, A., R. Taktela, E. Tholix, K. Vuorinen, G. Blanco, L. Risteli, and J. Ris-
teli. 1997. Aggressive breast cancer leads to discrepant serum levels of the
type I procollagen propeptides PINP and PICP. Cancer Res. 57:5517–5520.
Koch, A.E., M.M. Halloran, C.J. Haskell, S.R. Manisha, P.J. Polverini. 1995. An-
giogenesis mediated by soluble forms of E-selectin and vascular cell adhesion
molecule-1. Nature. 376:517–519.
Liotta, L.A., P.A. Steeg, and W.G. Stetler-Stevenson. 1991. Cancer metastasis and
angiogenesis: an imbalance of positive and negative regulation. Cell. 64:327–
336.
Messent, A.J., D.S. Tuckwell, V. Knauper, M.J. Humphries, G. Murphy, and J.
Gavrilovic. 1998. Effects of collagenase-cleavage of type I collagen on  2 1
integrin mediated cell adhesion. J. Cell Sci. 111:1127–1135.
Montgomery, A.M.P., R.A. Reisfeld, and D.A. Cheresh. 1994. Integrin  v 3 res-
cues melanoma cells from apoptosis in a three-dimensional dermal collagen.
Proc. Natl. Acad. Sci. USA. 91:8856–8860.
O’Reilly, M.S., M.S. Holmgren, L. Shing, Y. Chen, R.A. Rosenthal, M. Moszes,
W.W. Lane, Y. Cao, E.H. Sage, and J. Folkman. 1994. Angiostatin: a novel
angiogenesis inhibitor that mediates the suppression of metastases by lewis
lung carcinoma. Cell. 79:315–328.
Petitclerc, E., S. Stromblad, T.L. von Schalsacha, F. Mitjans, J. Piutats, A.M.P.
Montgomery, D.A. Cheresh, and P.C. Brooks. 1999. Integrin  v 3 pro-
motes M21 melanoma growth in human skin by regulating tumor cell sur-
vival. Cancer Res. 59:2724–2730.Cryptic site of collagen IV in angiogenesis | Xu et al. 1079
Rak, J., J. Filmus, G. Finkenzeller, S. Grugel, D. Marme, and R.S. Kerbel. 1995.
Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 14:
263–277.
Risau, W., and V. Lemmon. 1988. Changes in vascular extracellular matrix during
embryonic vasculogenesis and angiogenesis. Dev. Biol. 125:441–450.
Schnaper, W.H., D.S. Grant, W.G. Stetler-Stevenson, R. Fridaman, G. D’razi,
A.N. Murphy, R.E. Bird, M. Hoythya, T.R. Fuerst, D.L. French, J.P. Quig-
ley, and H.K. Kleinman. 1993. Type IV collagenases and TIMPs modulate
endothelial cell morphogenesis in vitro. J. Cell. Physiol. 156:235–246.
Senger, D.R., and C.A. Perruzzi. 1996. Cell migration promoted by a potent
RGDS-containing thrombin-cleavage fragment of osteopontin. Biochim.
Biophys. Acta. 1314:13–24.
Smith, J.W., and D.A. Cheresh. 1988. The Arg-Gly-Asp binding domain of the
vitronectin receptor. J. Biol. Chem. 263:18726–18731.
Stetler-Stevenson, W.G. 1999. Matrix metalloproteinases in angiogenesis: a mov-
ing target for therapeutic intervention. J. Clin. Invest. 103:1237–1241.
Suri, C., P.F. Jones, S. Patan, S. Bartunkova, P.C. Maisonpierre, S. Davis, T.N.
Sato, and G.D. Yancopoulos. 1996. Requisite role of Angiopoietin-1, a
ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 87:
1171–1180.
Timpl, R. 1996. Macromolecular organization of basement membranes. Curr.
Opin. Cell Biol. 8:618–624.
Timpl, R., and J.C. Brown. 1995. Supramolecular assembly of basement mem-
branes. Bioessays. 18:123–132.
Tsai, L.-H. 1998. Stuck on the ECM. Trends Cell Biol. 8:192–295.
Vu, T., M.J. Shipley, G. Bergers, J.E. Berger, J.A. Helms, D. Hanahan, S.D. Sha-
piro, R.M. Senior, and Z. Werb. 1998. MMP-9/gelatinase B is a key regula-
tor of growth plate angiogenesis and apoptosis of hypertrophic chondro-
cytes. Cell. 93:411–422.
Weidner, N., J.P. Semple, W.R. Welch, and J. Folkman. 1991. Tumor angiogene-
sis and metastasis, correlation in invasive breast carcinoma. N. Engl. J. Med.
324:1–8.
Weidner, N., J. Folkman, F. Pozza, P. Bevilacqua, E.N. Allred, D.H. Moore, S.
Meli, and G. Gasparini. 1992. Tumor angiogenesis: a new significant and
independent prognostic indicator in early-stage breast carcinoma. J. Natl.
Cancer Inst. 84:1875–1887.
Werb, Z., T. Vu, J.L. Rinkenberger, and L.M. Coussens. 1999. Matrix-degrading
proteases and angiogenesis during development and tumor formation.
APMIS. 107:11–18.
Xu, J., D. Rodriguez, J.J. Kim, and P.C. Brooks. 2000. Generation of monoclonal
antibodies to cryptic collagen sites by using subtractive immunization. Hy-
bridoma. 19:375–385.